Syntara Unveils New Phase 2 Data for Myelofibrosis Drug in Investor Webinar
Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.
- Investor webinar scheduled for 13 June 2025 to discuss Phase 2 interim data
- SNT-5505 targets myelofibrosis with Fast Track and Orphan Drug designations
- Data to be presented at European Hematology Association 2025 Congress
- SNT-5505 studied in combination with JAK inhibitor for suboptimal responders
- Additional Phase 1c/2 studies planned for related blood cancers
Syntara’s Upcoming Data Reveal
Clinical-stage biotech Syntara Limited (ASX – SNT) is preparing to share new interim data from its Phase 2 study of SNT-5505, a drug candidate aimed at treating myelofibrosis, a rare and debilitating bone marrow cancer. The company will host an investor webinar on 13 June 2025, where CEO Gary Phillips will present the latest findings ahead of their formal unveiling at the European Hematology Association Congress in Milan.
SNT-5505’s Strategic Position
SNT-5505 has attracted regulatory attention, having secured both Fast Track Designation and Orphan Drug status from the FDA, underscoring its potential in addressing an unmet medical need. The drug’s mechanism targets the extracellular matrix dysfunction that drives fibrosis in the bone marrow, which leads to impaired blood cell production. Early Phase 2a results as a monotherapy were encouraging, prompting further investigation of SNT-5505 in combination with a JAK inhibitor for patients who have shown suboptimal responses to existing treatments.
Broader Pipeline and Collaborations
Beyond myelofibrosis, Syntara is advancing additional studies for related blood cancers, including myelodysplastic syndrome, with two Phase 1c/2 trials expected to begin recruitment soon. The company also pursues innovative programs targeting fibrosis and inflammation in other organs, collaborating with notable experts such as Professor Fiona Wood and Parkinson’s UK. These efforts include developing pan-LOX inhibitors for scar prevention and a novel compound aimed at neurodegenerative disease progression.
Investor Engagement and Market Implications
The upcoming webinar offers shareholders and interested parties a direct line to management insights and the opportunity to submit questions live. While the announcement stops short of disclosing detailed clinical outcomes, the timing and regulatory context suggest that Syntara is positioning itself for potential partnerships or further clinical milestones. Investors will be watching closely for how these data might influence the company’s valuation and strategic direction.
Bottom Line?
Syntara’s Phase 2 data release could be a pivotal moment, setting the stage for next steps in clinical development and market positioning.
Questions in the middle?
- What specific efficacy and safety outcomes does the new Phase 2 data reveal for SNT-5505?
- How will the combination with JAK inhibitors impact the drug’s commercial prospects?
- What timelines and strategies does Syntara have for partnering or advancing its broader pipeline?